Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients
Publication: Cancer Research
Ramona Woitek, Mary McLean , Stephan Ursprung, Oscar M Ruedae, Raquel Manzano Garcia, Matthew Locke, Lucian Beer, Gabrielle Baxter, Leonardo Rundo, Elena Provenzano , Joshua Kaggie , Andrew Patterson, Amy Frarya, Johanna Field-Raynera,b , Vasiliki Papalouka , Justine Kaneg, Arnold Benjamin, Andrew B Gill , Andrew Priest , David Lewis, Roslin Russell, Ashley Grimmera, , Brian Whitea , Beth Latimer-Bowmana, , Ilse Patterson, Amy Schiller , Bruno Carmo , Rhys Slough , Titus Lanzk , James Wason, Rolf Schultel, Suet-Feung Chine, Martin J Graves, Fiona J Gilbert, Jean E Abraham, Carlos Caldase, Kevin M Brindle , Evis Sala Ferdia A Gallagher
8 October 2021
Summary
Hyperpolarised carbon-13 MRI was used to detect response to neoadjuvant chemotherapy in patients with early breast cancer around one week after the start of treatment.